Clinical Scorecard: ctDNA Test Guides Breast Care in Elderly

At a Glance

Key Highlights

• ctDNA testing can identify patients who may avoid surgery and rely on endocrine therapy.
• Persistent ctDNA after 6 months indicates tumor progression risk.
• Negative ctDNA at baseline correlates with no disease progression.
• ctDNA testing allows for decentralized and frequent monitoring.
• Pretreatment ctDNA positivity is linked to higher progression risk.

Guideline-Based Recommendations

Diagnosis

• Use ctDNA testing to assess tumor dynamics and treatment response.

Management

• Consider endocrine therapy for ctDNA-negative patients to avoid surgery.

Monitoring & Follow-up

• Implement routine ctDNA testing for ongoing disease monitoring.

Risks

• Avoid escalation to surgery or radiation in ctDNA-negative patients due to morbidity.

Patient & Prescribing Data

Elderly women with estrogen receptor-positive breast cancer

ctDNA can guide treatment decisions and monitor disease progression.

Clinical Best Practices

• Integrate ctDNA testing into routine care for personalized treatment pathways.
• Utilize ctDNA as a complementary tool alongside traditional pathology markers.

References

• Clinical Cancer Research